(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges

por den Broeder, Alfons A, den Broeder, Nathan, Verhoef, Lise M
Publicado 2021

Time to achieve remission determines time to be in remission

por Schipper, Lydia G, Fransen, Jaap, den Broeder, Alfons A, Van Riel, Piet LCM
Publicado 2010

Commentary: Autoimmune diseases in patients with myotonic dystrophy type 2

por Damen, Manon J., den Broeder, Alfons A., Voermans, Nicol C., Tieleman, Alide A.
Publicado 2022

Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report

por Schoffelen, Teske, den Broeder, Alfons A, Nabuurs-Franssen, Marrigje, van Deuren, Marcel, Sprong, Tom
Publicado 2014

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search

por Verhoef, Lise M., Tweehuysen, Lieke, Hulscher, Marlies E., Fautrel, Bruno, den Broeder, Alfons A.
Publicado 2017

The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study

por Hoogeboom, Thomas J, de Bie, Rob A, den Broeder, Alfons A, van den Ende, Cornelia HM
Publicado 2012

Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study

por Opdam, Merel A A, Vriezekolk, Johanna E, Broen, J, den Broeder, Alfons A, Verhoef, Lise M
Publicado 2023

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and...

por Geurts-Voerman, Gerlienke E., Verhoef, Lise M., van den Bemt, Bart J. F., den Broeder, Alfons A.
Publicado 2020

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

por Marsman, Diane E., Bolhuis, Thomas E., den Broeder, Nathan, den Broeder, Alfons A., van der Maas, Aatke
Publicado 2022

Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Final...

por Peeters, Iris Rose, den Broeder, Alfons A., Taylor, William J, den Broeder, Nathan, Flendrie, Marcel, van Herwaarden, Noortje
Publicado 2023

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis

por Zwikker, Hanneke E, van Dulmen, Sandra, den Broeder, Alfons A, van den Bemt, Bart J, van den Ende, Cornelia H
Publicado 2014

Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes

por Jansen, Fenna M, Vavricka, Stephan R, den Broeder, Alfons A, de Jong, Elke MGJ, Hoentjen, Frank, van Dop, Willemijn A
Publicado 2020

Non-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trial

por Hoogeboom, Thomas J, Stukstette, Mirelle JPM, de Bie, Rob A, Cornelissen, Jessica, den Broeder, Alfons A, van den Ende, Cornelia HM
Publicado 2010

Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline singl...

por Hoogeboom, Thomas J, Kwakkenbos, Linda, Rietveld, Leonie, den Broeder, Alfons A, de Bie, Rob A, van den Ende, Cornelia H M
Publicado 2012

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study

por Bouman, Chantal A M, Tweehuysen, Lieke, Haverkort, Dieneke, van den Ende, Cornelia H, van der Maas, Aatke, den Broeder, Alfons A
Publicado 2018

Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review

por Wientjes, Maike H M, den Broeder, Alfons A, Welsing, Paco M J, Verhoef, Lise M, van den Bemt, Bart J F
Publicado 2022

What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis

por Messelink, Marianne A, den Broeder, Alfons A, Marinelli, Florine E, Michgels, Edwin, Verschueren, P, Aletaha, Daniel, Tekstra, Janneke, Welsing, Paco M J
Publicado 2023

Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients

por Damen, Michelle S. M. A., Schraa, Kiki, Tweehuysen, Lieke, den Broeder, Alfons A., Netea, Mihai G., Popa, Calin D., Joosten, Leo A. B.
Publicado 2018

Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit

por Ulijn, Evy, den Broeder, Alfons A, Boers, Nadine, Gotthardt, Martin, Bouman, Chantal A M, Landewé, Robert, den Broeder, Nathan, van Herwaarden, Noortje
Publicado 2022

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an o...

por van der Maas, Aatke, van den Bemt, Bart JF, Wolbink, Gertjan, van den Hoogen, Frank HJ, van Riel, Piet LCM, den Broeder, Alfons A
Publicado 2012